New research suggests that the use of GLP-1 drugs can increase the risk of developing a different serious condition by 30%. The study found that 4% of Glp-1 users with obesity and Type 2 diabetes developed osteoporosis, compared to only 3% among non-users. The study also found that osteomalacia, a related condition in which bones soften, occurred twice as often among GLP1 users. The research was observational and did not factor in diet, exercise or vitamin supplementation. The FDA currently lists “increased risk of bone fracture in older adults and women” on its label for semaglutide. Experts suggest that the study should not discourage the prescription of these drugs but rather encourage providers to provide patients with guidance on protein intake, nutrition, physical activity, and monitoring of bone health.